• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 9 Aug

    Quoin Pharmaceuticals’ Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders

    NEW YORK, NY - (NewMediaWire) - August 09, 2023 - PCG Digital --Quoin Pharmaceuticals (Nasdaq:QNRX), a clinical stage pharmaceutical company specializing in rare and orphan diseases, has achieved significant milestones in its mission to deliver the first approved treatment for Netherton Syndrome, a rare hereditary genetic disease. The Company recently… Read More..

    Share this:
  • 9 Aug

    Oncocyte Regains Compliance With Nasdaq Listing Requirements

    IRVINE, CA / ACCESSWIRE / August 9, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing… Read More..

    Share this:
  • 28 Jul

    Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study

    KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. ("LEXX Nutra"). The establishment of LEXX Nutra is in keeping with Lexaria's… Read More..

    Share this:
« Previous 1 … 140 141 142 143 144 … 239 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact